receptor partial agonist. Selectively binds to α
3 and α
5 subunits (Ki
values are 0.79, 0.67, 0.67 and 2.25 nM respectively) but displays no efficacy at α
1-sparing). Exhibits non-sedative anxiolytic, antinociceptive and anti-inflammatory activity in vivo
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Manufactured and sold under license from Merck & Co., Inc. for use solely for preclinical research purposes (ie: not for administration to or other use in humans)
Subtype-selective GABAergic drugs facilitate extinction of mouse operant behaviour.
McCabe et al.
Differential behavioural effects of low efficacy positive GABAA modulators in combination with benzodiazepines and a neuroactive steroid in rhesus monkeys.
McMahon and France
Reversal of pathological pain through specific spinal GABAA receptor subtypes.
Knabl et al.